Streptokinase (SK) is a thrombolytic agent having broad applications in treatment of various diseases like
ischemia, Budd-Chiari syndrome, myocardial infarction, brain stroke and myocardial infarction. Strain
improvement is an important approach for its hyper production. In this connection, wild bacterial strain
Streptococcus equisimilis was mutagenized using ethidium bromide and UV radiation. The colonies (15
each) showing > 1% survival rate at 150 min of UV exposure and 12 % survival at 0.5 mg/ml of ethidium
bromide for 120 min were selected. Casein hydrolytic assay identified EB3, EB4, EB6, EB7, EB9, EB11,
EB13, UV2, UV4, UV6, UV7, UV9, UV11, UV12 and UV 15 mutants producing halo zones. Percentage
blood clot lysis led to screening of mutants UV 2, UV 6, UV 7, UV 9, UV 11, UV 12, UV 15 and EB 3,
EB 4, EB 11, EB 13 with hyperactivity as compared to wild bacterial strain. Out of the total 15 isolates of
EtBr-treated strains, EB4 gave the maximum enzyme activity (7.3 ± 0.005 U ml-1) with a zone diameter
of 6 mm. While UV6 was found to be the best UV-induced mutant with an enzyme activity of 20.333 ±
0.006A U ml-1 and 16 mm of zone diameter. The current results indicated 400 % and 146% enhanced SK
activity in mutants UV6 and EB4, respectively, compared to wild type. UV6 also exhibited the highest
enzyme activity (14.667± 6.5) after precipitation with ammunium sulphate, at concentrations as low as 30
µl. Optimized conditions for maximum yield of mutant SK included CSL 6%, 24 h. of fermentation, pH
7.5, 37oC, KH2PO4 0.04%, K2HPO4, NaHCO3 0.15% and 0.015% CH3COONa. The results indicated that
UV is the most effective mutagen for hyper-production of SK. Mutant strain UV6 has the potential for
enhanced SK production with commercial applications.